Loading…

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Saved in:

Bibliographic Details
Published in:	Blood 2024-11, Vol.144 (Supplement 1), p.362-362
Main Authors:	Zweegman, Sonja, Facon, Thierry, Hungria, Vania, Bahlis, Nizar J., Venner, Christopher P., Braunstein, Marc, Pour, Luděk, Marti Tutusaus, Josep, Basu, Supratik, Cohen, Yael C., Matsumoto, Morio, Suzuki, Kenshi, Hulin, Cyrille, Grosicki, Sebastian, Legiec, Wojciech Maciej, Beksac, Meral, Maiolino, Angelo, Takamatsu, Hiroyuki, Perrot, Aurore, Turgut, Mehmet, Liu, Weiping, Wang, Jianping, Chastain, Katherine, Vermeulen, Jessica, Krevvata, Maria, Lopez-Masi, Lorena, Carey, Jodi, Rowe, Melissa, Carson, Robin, Usmani, Saad Z.
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!